BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29158144)

  • 1. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
    Dietl B; Sánchez I; Arcenillas P; Cuchi E; Gómez L; González de Molina FJ; Boix-Palop L; Nicolás J; Calbo E
    Int J Antimicrob Agents; 2018 Mar; 51(3):498-502. PubMed ID: 29158144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.
    Castaldo N; Givone F; Peghin M; Righi E; Sartor A; Bassetti M
    J Glob Antimicrob Resist; 2017 Jun; 9():100-102. PubMed ID: 28495526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
    Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
    Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
    Sousa Dominguez A; Perez-Rodríguez MT; Nodar A; Martinez-Lamas L; Perez-Landeiro A; Crespo Casal M
    J Antimicrob Chemother; 2017 Apr; 72(4):1262-1263. PubMed ID: 27999042
    [No Abstract]   [Full Text] [Related]  

  • 5. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
    Buonomo AR; Maraolo AE; Scotto R; Foggia M; Zappulo E; Congera P; Parente S; Gentile I
    Infection; 2020 Apr; 48(2):303-307. PubMed ID: 31981091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
    MacVane SH; Pandey R; Steed LL; Kreiswirth BN; Chen L
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.
    Gentile I; Buonomo AR; Maraolo AE; Scotto R; De Zottis F; Di Renzo G; Borgia G
    J Antimicrob Chemother; 2017 Sep; 72(9):2678-2679. PubMed ID: 28575437
    [No Abstract]   [Full Text] [Related]  

  • 9. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M; Sutherland C; Nicolau DP
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Pragsam AK; Kumar DT; Doss CGP; Iyadurai R; Satyendra S; Rodrigues C; Joshi S; Roy I; Chaudhuri BN; Chitnis DS; Tapan D; Veeraraghavan B
    Indian J Med Microbiol; 2018; 36(1):127-130. PubMed ID: 29735843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.
    Hakki M; Lewis JS
    Infection; 2018 Jun; 46(3):431-434. PubMed ID: 29460229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
    Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
    Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of a complex orthopaedic infection due to extensively drug-resistant
    Hassan S; Kahn MD; Saraiya N; Nori P
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29305368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
    Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
    Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of multidrug-resistant
    Kurtzhalts KE; Mergenhagen KA; Manohar A; Berenson CS
    BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28363945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam.
    Monterrubio-Villar J; Rodríguez-Garrido S; Jiménez-Delgado JD
    Rev Esp Quimioter; 2018 Aug; 31(4):374-375. PubMed ID: 30014680
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa.
    Dinh A; Wyplosz B; Kernéis S; Lebeaux D; Bouchand F; Duran C; Béraud G; Lazaro P; Davido B; Hénard S; Canouï E; Ferry T; Wolff M
    Int J Antimicrob Agents; 2017 Jun; 49(6):782-783. PubMed ID: 28412272
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.
    Haidar G; Philips NJ; Shields RK; Snyder D; Cheng S; Potoski BA; Doi Y; Hao B; Press EG; Cooper VS; Clancy CJ; Nguyen MH
    Clin Infect Dis; 2017 Jul; 65(1):110-120. PubMed ID: 29017262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.
    Aitken SL; Kontoyiannis DP; DePombo AM; Bhatti MM; Tverdek FP; Gettys SC; Nicolau DP; Nunez CA
    Pediatr Infect Dis J; 2016 Sep; 35(9):1040-2. PubMed ID: 27254038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.